E. C. Quant

1.2k total citations
25 papers, 871 citations indexed

About

E. C. Quant is a scholar working on Genetics, Neurology and Oncology. According to data from OpenAlex, E. C. Quant has authored 25 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 7 papers in Neurology and 7 papers in Oncology. Recurrent topics in E. C. Quant's work include Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (6 papers) and Cancer Treatment and Pharmacology (6 papers). E. C. Quant is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (6 papers) and Cancer Treatment and Pharmacology (6 papers). E. C. Quant collaborates with scholars based in United States and Canada. E. C. Quant's co-authors include Patrick Y. Wen, Jan Drappatz, Andrew D. Norden, Rameen Beroukhim, Lisa Doherty, A. S. Ciampa, Debra C. LaFrankie, Santosh Kesari, Alona Muzikansky and Rajeev H. Muni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Genomics.

In The Last Decade

E. C. Quant

25 papers receiving 847 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. C. Quant United States 14 494 261 226 207 196 25 871
Stergios Zacharoulis United States 20 580 1.2× 355 1.4× 238 1.1× 175 0.8× 291 1.5× 59 1.2k
Christopher McPherson United States 20 335 0.7× 257 1.0× 422 1.9× 292 1.4× 319 1.6× 33 1.2k
Amedeo A. Azizi Austria 17 435 0.9× 335 1.3× 224 1.0× 180 0.9× 284 1.4× 76 907
Frederick G. Barker United States 16 527 1.1× 235 0.9× 304 1.3× 282 1.4× 140 0.7× 45 1.1k
Anu Banerjee United States 16 597 1.2× 355 1.4× 152 0.7× 150 0.7× 282 1.4× 32 956
George C. Bobustuc United States 13 221 0.4× 365 1.4× 219 1.0× 204 1.0× 193 1.0× 24 983
Marc H.A. Jansen Netherlands 18 497 1.0× 261 1.0× 178 0.8× 118 0.6× 224 1.1× 42 921
Elia Guadagno Italy 20 240 0.5× 274 1.0× 152 0.7× 379 1.8× 205 1.0× 74 1.1k
William Shapiro United States 10 498 1.0× 154 0.6× 333 1.5× 105 0.5× 244 1.2× 16 870
Woo‐Youl Jang South Korea 18 286 0.6× 209 0.8× 175 0.8× 335 1.6× 115 0.6× 60 797

Countries citing papers authored by E. C. Quant

Since Specialization
Citations

This map shows the geographic impact of E. C. Quant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. C. Quant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. C. Quant more than expected).

Fields of papers citing papers by E. C. Quant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. C. Quant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. C. Quant. The network helps show where E. C. Quant may publish in the future.

Co-authorship network of co-authors of E. C. Quant

This figure shows the co-authorship network connecting the top 25 collaborators of E. C. Quant. A scholar is included among the top collaborators of E. C. Quant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. C. Quant. E. C. Quant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raizer, Jeffrey J., Elena Pentsova, Antonio Omuro, et al.. (2014). AT-47 * PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES. Neuro-Oncology. 16(suppl 5). v19–v19. 14 indexed citations
2.
Gerstner, Elizabeth R., Kyrre E. Emblem, S. Andrew, et al.. (2012). Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.. Journal of Clinical Oncology. 30(15_suppl). 2009–2009. 10 indexed citations
3.
Norden, Andrew D., Shota Tanaka, Jan Drappatz, et al.. (2011). Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. Journal of Neuro-Oncology. 106(1). 121–125. 71 indexed citations
4.
Kelly, Paul J., Nancy U. Lin, Elizabeth B. Claus, et al.. (2011). Salvage stereotactic radiosurgery for breast cancer brain metastases. Cancer. 118(8). 2014–2020. 29 indexed citations
5.
Quant, E. C., Tracy T. Batchelor, Andrew B. Lassman, et al.. (2011). Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 29(15_suppl). 2069–2069. 8 indexed citations
6.
Drappatz, Jan, Jeffrey J. Raizer, David Schiff, et al.. (2011). A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).. Journal of Clinical Oncology. 29(15_suppl). 2050–2050. 6 indexed citations
7.
Quant, E. C., et al.. (2010). The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta‐analysis. Clinical Otolaryngology. 35(1). 54–54. 2 indexed citations
8.
Scott, Brian J., et al.. (2010). Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology. 12(6). 603–607. 51 indexed citations
9.
Merrell, Ryan, et al.. (2010). Advances in Treatment Options for High-grade Glioma - Current Status and Future Perspectives. European Neurological Review. 5(1). 49–49. 1 indexed citations
10.
Quant, E. C. & Patrick Y. Wen. (2010). Response Assessment in Neuro-Oncology. Current Oncology Reports. 13(1). 50–56. 85 indexed citations
11.
Merrell, Ryan, et al.. (2010). Advances in Treatment Options for High-grade Glioma—Current Status and Future Perspectives. 6(1). 55–55. 1 indexed citations
12.
Lu‐Emerson, Christine, Andrew D. Norden, Jan Drappatz, et al.. (2010). Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. Journal of Neuro-Oncology. 104(1). 287–291. 54 indexed citations
13.
Quant, E. C., Jan Drappatz, Patrick Y. Wen, & Andrew D. Norden. (2010). Recurrent High-Grade Glioma. Current Treatment Options in Neurology. 12(4). 321–333. 26 indexed citations
14.
Wen, Patrick Y., Andrew D. Norden, Jan Drappatz, & E. C. Quant. (2010). Response Assessment Challenges in Clinical Trials of Gliomas. Current Oncology Reports. 12(1). 68–75. 30 indexed citations
15.
Wen, Patrick Y., E. C. Quant, Jan Drappatz, Rameen Beroukhim, & Andrew D. Norden. (2010). Medical therapies for meningiomas. Journal of Neuro-Oncology. 99(3). 365–378. 121 indexed citations
16.
Quant, E. C. & Patrick Y. Wen. (2010). Novel Medical Therapeutics in Glioblastomas, Including Targeted Molecular Therapies, Current and Future Clinical Trials. Neuroimaging Clinics of North America. 20(3). 425–448. 14 indexed citations
17.
Lu‐Emerson, Christine, Andrew D. Norden, Jan Drappatz, et al.. (2010). Retrospective study of dasatinib in recurrent high-grade glioma (HGG) patients who failed bevacizumab.. Journal of Clinical Oncology. 28(15_suppl). e12525–e12525. 1 indexed citations
18.
Quant, E. C., et al.. (2009). The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ. 339(sep07 1). b3354–b3354. 94 indexed citations
19.
Quant, E. C., Andrew D. Norden, Jan Drappatz, et al.. (2009). Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-Oncology. 11(5). 550–555. 141 indexed citations
20.
Uppaluri, Ravindra, Amy P. Schmidt, E. C. Quant, et al.. (2001). Transcript Map of the 8p23 Putative Tumor Suppressor Region. Genomics. 75(1-3). 17–25. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stergios Zacharoulis Breakdown of academic impact, for papers by Christopher McPherson Breakdown of academic impact, for papers by Amedeo A. Azizi Breakdown of academic impact, for papers by Frederick G. Barker Breakdown of academic impact, for papers by Anu Banerjee Breakdown of academic impact, for papers by George C. Bobustuc Breakdown of academic impact, for papers by Marc H.A. Jansen Breakdown of academic impact, for papers by Elia Guadagno Breakdown of academic impact, for papers by William Shapiro Breakdown of academic impact, for papers by Woo‐Youl Jang
Rankless by CCL
2026